Selective Antimicrobial Compounds for Pathogen-Targeted Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial compounds are often broad-spectrum, inhibiting both pathogenic and commensal microbes, leading to increased resistance in pathogenic microbes and undesirable side effects, necessitating higher doses that can harm both animals and the environment.
Innovation Solution
Development of selective antimicrobial compounds, such as those with structures defined by Formulae 1A, 1B, or 1C, that preferentially target and inhibit pathogenic microbes like bacteria, viruses, and fungi over commensal microbes, using specific structures and linkers to achieve selective inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antimicrobial compounds are used to inhibit pathogenic microbes, then microbial infection is treated, but commensal microbes are also inhibited leading to increased resistance and undesirable side effects
Solution Approach 1:
The patent applies local quality by designing antimicrobial compounds with specific molecular structures (Formulae 1A, 1B, 1C) that have differentiated activity against different microbial types. The compounds exhibit selective inhibition characteristics where pathogenic microbes are targeted more effectively than commensal microbes, achieving local differentiation in microbial susceptibility rather than uniform broad-spectrum activity.
Solution Approach 2:
The patent utilizes parameter changes by modifying molecular parameters of the antimicrobial compounds through various substituents and structural variations in Formulae 1A, 1B, and 1C. These parameter changes enable fine-tuning of the compounds' antimicrobial activity to achieve selective inhibition of pathogenic microbes while reducing impact on commensal microbes.
2Reliability
If higher doses of antimicrobial treatments are required to achieve efficacy against resistant strains, then pathogenic microbial infection is controlled, but toxicity to animals and environment increases
Solution Approach 1:
The patent employs parameter changes by developing a series of antimicrobial compounds with varied molecular structures (Formulae 1A, 1B, 1C) that differ in their antimicrobial activity parameters. This allows achieving effective inhibition of resistant strains at lower doses compared to traditional broad-spectrum antimicrobials, thereby reducing toxicity to animals and the environment while maintaining efficacy.
3Reliability
If traditional antimicrobial compounds are used to treat infections, then pathogenic microbes are inhibited, but commensal microbes are also affected disrupting microbial balance
Solution Approach 1:
The patent applies local quality by creating antimicrobial compounds with differentiated selective activity. The compounds (Formulae 1A, 1B, 1C) exhibit varying degrees of inhibition against different microbial groups, allowing effective treatment of infections caused by pathogenic microbes while preserving commensal microbial populations and maintaining microbial community balance.
Solution Approach 2:
The patent utilizes parameter changes through structural variations in the antimicrobial compounds to achieve selective inhibition profiles. By modifying molecular parameters across Formulae 1A, 1B, and 1C, the compounds can be optimized to target pathogenic microbes specifically, thereby treating infections without disrupting the stability and balance of commensal microbial communities.
Data Source
AI summary
A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;